Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Feb 15;32(6):671-691.
doi: 10.1515/revneuro-2020-0116. Print 2021 Aug 26.

Overview of COVID-19 and neurological complications

Nasrin Hosseini  1 , Shabnam Nadjafi  1 , Behnaz Ashtary  2
Affiliations
Free article
Review

Overview of COVID-19 and neurological complications

Nasrin Hosseini et al. Rev Neurosci. .
Free article

Abstract

The sudden and storming onset of coronavirus 2 infection (severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2]) was associated by severe acute respiratory syndrome. Recently, corona virus disease 19 (COVID-19) has appeared as a pandemic throughout the world. The mutational nature of the virus, along with the different means of entering and spreading throughout the body has involved different organs. Thus, patients are faced with a wide range of symptoms and signs. Neurological symptoms, such as anosmia, agnosia, stroke, paralysis, cranial nerve deficits, encephalopathy, meningitis, delirium and seizures, are reported as common complications affecting the course of the disease and its treatment. In this review, special attention was paid to reports that addressed the acute or chronic neurological manifestations in COVID-19 patients who may present acute respiratory syndrome or not. Moreover, we discussed the central (CNS) and peripheral nervous system (PNS) complications in SARS-Cov2-infected patients, and also the pathophysiology of neurological abnormalities in COVID-19.

Keywords: Alzheimer’s disease; Guillain Barre syndrome; cerebrovascular disease; corona virus 2; encephalopathy; multiple sclerosis.

PubMed Disclaimer

References

    1. Abdennour, L., Zeghal, C., Deme, M., and Puybasset, L. (2012). Interaction brain-lungs. Ann. Fr. Anesth. Reanim. 31: e101–e107, https://doi.org/10.1016/j.annfar.2012.04.013.
    1. Ahmad, I. and Rathore, F.A. (2020). Neurological manifestations and complications of COVID-19: a literature review. J. Clin. Neurosci. 77: 8–12, https://doi.org/10.1016/j.jocn.2020.05.017.
    1. Ahmed, M.U., Hanif, M., Ali, M.J., Haider, M.A., Kherani, D., Memon, G.M., and Sattar, A. (2020). Neurological manifestations of COVID-19 (SARS-CoV-2): a review. Front. Neurol. 11: 518, https://doi.org/10.3389/fneur.2020.00518.
    1. Akhoundi, F.H., Sahraian, M.A., and Moghadasi, A.N. (2020). Neuropsychiatric and cognitive effects of the COVID-19 outbreak on multiple sclerosis patients. Mult. Scler. Relat. Disord. 41: 102164.
    1. Al Saiegh, F., Ghosh, R., Leibold, A., Avery, M.B., Schmidt, R.F., Theofanis, T., Mouchtouris, N., Philipp, L., Peiper, S.C., and Wang, Z.-X. (2020). Status of SARS-CoV-2 in cerebrospinal fluid of patients with COVID-19 and stroke. J. Neurol. Neurosurg. Psychiatr. 1: 846–848, https://doi.org/10.1136/jnnp-2020-323522.

Publication types

LinkOut - more resources